phenyl 3-fluoro-4-(hydroxymethyl)phenylcarbamate | 1402585-33-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: phenyl 3-fluoro-4-(hydroxymethyl)phenylcarbamate
• 英文别名: Phenyl (3-fluoro-4-(hydroxymethyl)phenyl)carbamate；phenyl N-[3-fluoro-4-(hydroxymethyl)phenyl]carbamate
• CAS: 1402585-33-4
• 化学式: C₁₄H₁₂FNO₃
• 分子量: 261.253
• InChiKey: PRQOVURDJJEVDG-UHFFFAOYSA-N

物化性质

• 沸点：
  382.1±42.0 °C(Predicted)
• 密度：
  1.357±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313
• 危险性描述：
  H315,H319

反应信息

• 作为反应物：
  描述：

  (1-(3-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)methanamine 、 phenyl 3-fluoro-4-(hydroxymethyl)phenylcarbamate 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以47%的产率得到1-[[2-(3-chlorophenyl)-5-(trifluoromethyl)-2H-pyrazol-3-yl]-methyl]-3-[3-fluoro-4-(hydroxymethyl)-phenyl]-urea
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRAZOLYL-BASED CARBOXAMIDE AND UREA DERIVATIVES BEARING A PHENYL MOIETY SUBSTITUTED WITH A CO-CONTAINING GROUP AS VANILLOID RECEPTOR LIGANDS
  [FR] DÉRIVÉS DE CARBOXAMIDE ET D'URÉE À BASE DE PYRAZOLYLE SUBSTITUÉ PORTANT UN FRAGMENT PHÉNYLE REMPLACÉ PAR UN GROUPE CONTENANT CO COMME LIGANDS DES RÉCEPTEURS VANILLOÏDES

  摘要：

  该发明涉及取代吡唑基的羧酰胺和脲衍生物，其带有一个苯基被一个含CO基团取代的香草醛受体配体，以及含有这些化合物的药物组合物，还涉及这些化合物用于治疗和/或预防疼痛以及其他疾病和/或疾患。

  公开号：

  WO2013068467A1
• 作为产物：
  描述：

  2-氟-4-硝基苯甲酸 在 吡啶 、 甲醇 、 sodium tetrahydroborate 、 硫酸 、 palladium 10% on activated carbon 、 氢气 作用下， 以 乙酸乙酯 、 丙酮 为溶剂， 反应 11.0h， 生成 phenyl 3-fluoro-4-(hydroxymethyl)phenylcarbamate
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRAZOLYL-BASED CARBOXAMIDE AND UREA DERIVATIVES BEARING A PHENYL MOIETY SUBSTITUTED WITH A CO-CONTAINING GROUP AS VANILLOID RECEPTOR LIGANDS
  [FR] DÉRIVÉS DE CARBOXAMIDE ET D'URÉE À BASE DE PYRAZOLYLE SUBSTITUÉ PORTANT UN FRAGMENT PHÉNYLE REMPLACÉ PAR UN GROUPE CONTENANT CO COMME LIGANDS DES RÉCEPTEURS VANILLOÏDES

  摘要：

  该发明涉及取代吡唑基的羧酰胺和脲衍生物，其带有一个苯基被一个含CO基团取代的香草醛受体配体，以及含有这些化合物的药物组合物，还涉及这些化合物用于治疗和/或预防疼痛以及其他疾病和/或疾患。

  公开号：

  WO2013068467A1

文献信息

• [EN] SUBSTITUTED PYRAZOLYL-BASED CARBOXAMIDE AND UREA DERIVATIVES BEARING A PHENYL MOIETY SUBSTITUTED WITH AN O-CONTAINING GROUP AS VANILLOID RECEPTOR LIGANDS<br/>[FR] DÉRIVÉS DE CARBOXAMIDE ET D'URÉE À BASE DE PYRAZOLYLE SUBSTITUÉ PORTANT UN FRAGMENT PHÉNYLE REMPLACÉ PAR UN GROUPE CONTENANT O COMME LIGANDS DES RÉCEPTEURS VANILLOÏDES
  申请人：GRUENENTHAL GMBH

  公开号：WO2013068461A1

  公开（公告）日：2013-05-16

  The invention relates to substituted pyrazolyl-based carboxamide and urea derivatives of formula (Q) as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

  这项发明涉及以式(Q)的取代吡唑基羧酰胺和脲衍生物作为辣椒素受体配体，以及含有这些化合物的药物组合物，还涉及这些化合物用于治疗和/或预防疼痛以及其他疾病和/或紊乱。
• Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands
  申请人：FRANK Robert

  公开号：US20120258946A1

  公开（公告）日：2012-10-11

  Substituted phenylureas and phenylamides, processes for their preparation, pharmaceutical compositions containing these compounds, and the use of these compounds for preparing pharmaceutical compositions.

  取代苯基脲和苯基酰胺，其制备过程，含有这些化合物的制药组合物以及使用这些化合物制备制药组合物的用途。
• Substituted phenylureas and phenylamides as vanilloid receptor ligands
  申请人：Frank Robert

  公开号：US08946204B2

  公开（公告）日：2015-02-03

  Substituted phenylureas and phenylamides, processes for their preparation, pharmaceutical compositions containing these compounds, and the use of these compounds for preparing pharmaceutical compositions.

  取代苯脲和苯酰胺，其制备方法，含有这些化合物的药物组合物以及使用这些化合物制备药物组合物。
• Discovery of dual-acting opioid ligand and TRPV1 antagonists as novel therapeutic agents for pain
  作者：Hobin Lee、Songyeon Ahn、Jihyae Ann、Heejin Ha、Young Dong Yoo、Young Ho Kim、Ji-Young Hwang、Kwang-Hyun Hur、Choon-Gon Jang、Larry V. Pearce、Timothy E. Esch、Nancy E. Lewin、Peter M. Blumberg、Jeewoo Lee

  DOI：10.1016/j.ejmech.2019.111634

  日期：2019.11

  In order to discover a novel type of analgesic, we investigated dual activity ligands with TRPV1 antagonism and mu-opioid receptor affinity with the goal of eliciting synergistic analgesia while avoiding the side effects associated with single targeting. Based on a combination approach, a series of 4-benzyl-4-(dimethylamino)piperidinyl analogues were designed, synthesized and evaluated for their receptor activities. Among them, compound 49 exhibited the most promising dual-acting activity toward TRPV1 and the mu-opioid receptor in vitro. In vivo, 49 displayed potent, dose-dependent antinociceptive activity in both the 1st and 2nd phases in the formalin assay. Consistent with its postulated mechanism, we confirmed that in vivo, as in vitro, compound 49 both antagonized TRPV1 and functioned as a mu-opioid agonist. This result indicates that dual-acting TRPV1 antagonist/mu-opioid ligands can be made and represent a new and promising class of analgesic. (C) 2019 Elsevier Masson SAS. All rights reserved.
• Discovery of Nonpungent Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist as Strong Topical Analgesic
  作者：Jihyae Ann、Ho Shin Kim、Shivaji A. Thorat、Hee Kim、Hee-Jin Ha、Kwanghyun Choi、Young-Ho Kim、Minseok Kim、Sun Wook Hwang、Larry V. Pearce、Timothy E. Esch、Noe A. Turcios、Peter M. Blumberg、Jeewoo Lee

  DOI：10.1021/acs.jmedchem.9b01046

  日期：2020.1.9

  Paradoxically, some TRPV1 agonists are, at the organismal level, both nonpungent and clinically useful as topical analgesics. Here, we describe the scaled-up synthesis and characterization in mouse models of a novel, nonpungent vanilloid. Potent analgesic activity was observed in models of neuropathic pain, and the compound blocked capsaicin induced allodynia, showing dermal accumulation with little transdermal absorption. Finally, it displayed much weaker systemic toxicity compared to capsaicin and was negative in assays of genotoxicity.